The Foundation for Prader-Willi Research (FPWR) today announced a venture philanthropy investment in ConSynance Therapeutics, a clinical-stage biotechnology company developing CSTI-500, an investigational therapy for the treatment of behavioral dysre...
FPWR
Recent Posts
Skin picking is a common and challenging behavior seen in people with Prader-Willi syndrome (PWS), and for many families, it can be incredibly distressing.
For lack of a better phrase to emphasize the heaviness and intensity of the beginning: those days were hard.
Topics: Stories of Hope, hopefull
When our family learned that Miles had Prader-Willi syndrome, everything changed. I had never heard of PWS before, and I was in shock. I was scared and heartbroken for Josh and Carolyn. All I could think was, What are we going to do?
Topics: Stories of Hope, hopefull
Parents of children with Prader-Willi syndrome don’t need to be told that caregiving is hard — you live it every day. You juggle medical complexity, behavioral challenges, constant vigilance around food, and the emotional weight of advocating for you...
Topics: Mental Health, Research
A new clinical study is now enrolling individuals with Prader-Willi syndrome (PWS), offering families the opportunity to explore a potential new treatment for obesity and hyperphagia.
Topics: News, Clinical Trials Opportunities
Sleep challenges affect more than 70% of individuals with Prader-Willi syndrome (PWS). Excessive daytime sleepiness, disrupted nighttime sleep, altered REM patterns, and sleep-disordered breathing all contribute to a complex sleep profile that affect...
Topics: Mental Health, Behavior
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the tr...
Topics: News
Families living with Prader-Willi syndrome are changing how PWS is understood, studied, and treated.
